Complex Migraine Management
For complex migraine, use NSAIDs or triptans as first-line acute therapy, and initiate preventive therapy with topiramate, valproate, or CGRP monoclonal antibodies if attacks remain disabling despite optimized acute treatment, with onabotulinumtoxinA reserved specifically for chronic migraine (≥15 headache days/month). 1
Acute Treatment Strategy
First-Line Agents
Start with NSAIDs (ibuprofen 400 mg, aspirin, or diclofenac potassium) taken early in the headache phase 2. For moderate-to-severe attacks or when NSAIDs fail, advance immediately to triptans as second-line therapy 1, 2.
Combination Therapy
Combine triptans with fast-acting NSAIDs to prevent headache recurrence and improve efficacy 2. This combination approach addresses both the inflammatory and neurovascular components of migraine.
Third-Line Options
When triptans are contraindicated or ineffective, consider:
- Gepants (CGRP inhibitors) - newer agents without vascular contraindications 1, 3
- Ditans (lasmiditan) - avoid if patient needs to drive within 8 hours due to impairment risk 2
Adjunctive Therapy
Add prokinetic antiemetics (metoclopramide or domperidone) for nausea and vomiting 2.
Critical Pitfall
Avoid opioids, barbiturates, and oral ergot alkaloids - these have questionable efficacy, significant adverse effects, dependency risk, and potential toxicity 2. Warn patients that frequent acute medication use (>10 days/month for triptans/gepants, >15 days/month for NSAIDs) risks medication overuse headache 2.
Preventive Treatment Strategy
Indications for Prevention
Initiate preventive therapy when:
- Attacks remain disabling despite optimized acute therapy
- Patient experiences ≥2 significantly impaired days per month (not an absolute threshold)
- Severe, prolonged attacks occur
- Acute medication overuse is present 2
First-Line Preventive Agents
For episodic migraine, choose from:
- Topiramate or valproate (antiseizure medications)
- Lisinopril or angiotensin-receptor blockers
- Magnesium
- Memantine
- CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab)
- Atogepant (oral gepant) 1
For chronic migraine (≥15 headache days/month):
- OnabotulinumtoxinA is specifically indicated and should be offered 1
- Do NOT use onabotulinumtoxinA for episodic migraine 1
Important Negative Recommendation
Gabapentin is NOT recommended for episodic migraine prevention 1.
Titration and Trial Duration
- Oral preventives: Start low, titrate slowly to therapeutic dose. Assess efficacy after 2-3 months at adequate dose before switching 2
- CGRP monoclonal antibodies: Assess after 3-6 months (these work faster and don't require titration) 2, 4
- OnabotulinumtoxinA: Assess after 6-9 months 2
Counsel patients that preventive efficacy is rarely immediate - discourage premature discontinuation 2.
Non-Pharmacologic Interventions
Physical therapy and aerobic exercise can be used for both acute and preventive management 1. Consider neuromodulation devices for patients who prefer non-drug therapies, cannot tolerate medications, or have contraindications 4.
Algorithm for Treatment Selection
Assess attack severity and frequency
- Mild-moderate, infrequent → NSAIDs alone
- Moderate-severe → Triptans ± NSAIDs
- Vascular contraindications → Gepants or ditans
Evaluate need for prevention
- <15 headache days/month with disability → Oral preventives (topiramate, valproate, ARBs, CGRP mAbs, atogepant)
- ≥15 headache days/month → OnabotulinumtoxinA or CGRP mAbs
Monitor for medication overuse
- Track acute medication frequency monthly
- If overuse develops, initiate prevention and taper acute medications
Sequential trials if first preventive fails
- Switch after adequate trial duration (2-3 months for orals)
- Consider combination therapy or alternative mechanism
This evidence-based approach prioritizes quality of life and disability reduction while minimizing medication-related harm 1, 2.